Well-differentiated neuroendocrine tumours (NETs) are rare, slow-growing tumours. Chromogranin A (CgA) has replaced the 24-h urine collection of 5-hydroxyindoleacetic acid and has become the most important tumour marker in the monitoring of NET during and after treatment and is recommended by the European NeuroEndocrine Tumor Society ([@bib6]; [@bib8]). Chromogranin A is localised in the secretory granules of the neuroendocrine cells. Chromogranin A levels may also be elevated in other disease processes, such as prostate cancer, liver failure, cardiovascular diseases and renal failure ([@bib10]; [@bib7]; [@bib11]). However, the use of proton pump inhibitors (PPIs) is the most important reason for an elevated CgA level, not caused by NET ([@bib7]). Thus far, the effect of discontinuation of PPI therapy was not investigated. This study examines whether discontinuation of PPI treatment, or replacement by H~2~-receptor antagonist (H2RA) therapy, decreases or even normalises the unexplained elevation of CgA levels in patients with well-differentiated NET.

Materials and methods
=====================

For this prospective study, all patients diagnosed with well-differentiated NET visiting the Netherlands Cancer Institute between 2007 and 2009 with at least two available CgA measurements, were examined. Clinical data and medication were retrieved from medical records. Stage of disease was based on CT scans, or somatostatin receptor scintigraphy. Chromogranin A was determined with the CGA-RIA, a solid-phase, two-site immunoradiometric (CIS bio International, Gif-sur-Yvette, France) ([@bib1]; [@bib6]). The reference value in our laboratory was established as \<120 *μ*g l^−1^.

All patients with a normal CgA level during the study period were excluded from further examination. Patients with elevated CgA levels showing metastases or tumour progression were also excluded from further observation; these elevated CgA levels were attributed to tumour activity only. If patients showed elevated or increasing CgA levels that could not be attributed to the status of NET, the gastric acid inhibition treatment was registered. Those patients with unexpected elevated CgA levels and using PPI were asked to (temporarily) discontinue the PPI or to (temporarily) replace the PPI by H2RA treatment. After 2 weeks, the CgA level was measured again.

Wilcoxon paired tests and Mann--Whitney tests were applied to compare the CgA levels just before and 14 days after PPI discontinuation, and to compare change in CgA levels between patients who discontinued any acid suppressing therapy and patients who replaced PPI by H2RA. A change of \>40% was considered as a significant change in the comparison of serial measurements ([@bib3]).

Results
=======

[Table 1](#tbl1){ref-type="table"} presents the characteristics of 196 patients at the time of the first CgA measurement: a total of 55 patients showed normal CgA levels and 122 patients had at least one elevated CgA level that was attributed to the status of the disease, according to imaging; these patients were not monitored longer for this study.

The remaining 19 patients had elevated CgA levels that could not be attributed to the disease status: 11 patients with no evidence of disease (NED) after surgery and eight patients with stable metastatic disease (SD) ([Table 2](#tbl2){ref-type="table"}). All these patients used PPI (omeprazole 20--40 mg daily) for dyspepsia or pyrosis, mainly prescribed by their general practitioner. In case of severe pyrosis, PPI was replaced by H2RA (ranitidine 300 mg daily, *n*=7). The remaining patients discontinued the acid inhibition completely (*n*=12). All 19 patients experienced no discomfort from this temporary cease of PPI use.

In the 11 patients with NED, the median CgA level decreased from 390 *μ*g l^--1^ during PPI treatment to 56 *μ*g l^--1^ after discontinuation of PPI (*P*=0.003). At that time, nine patients showed normal CgA levels, while in two patients (patients 6 and 7), the CgA levels decreased by 81% and 89%, respectively. The eight patients with SD according to imaging, showed unexpected increase of CgA levels. After discontinuation of PPI, the median CgA level decreased from 618 *μ*g l^--1^ during PPI use to 318 *μ*g l^--1^ (*P*=0.012). In two patients (patients 16 and 19), CgA levels even normalised.

All patients except two (patients 15 and 18) reached the critical difference of CgA change of \>40% (33% and 35%, respectively). In 12 of the 19 patients with unexpected positive CgA levels who stopped all acid inhibition completely, CgA levels decreased by (median) 82% (range 33--89%). A similar trend was found in the seven patients who replaced PPI by H2RA: their CgA levels decreased by 77% (range 72--86%) (*P*=0.967).

Discussion
==========

In this study, we investigated the association of CgA levels and use of PPIs in patients treated for NET. High CgA levels were observed in 19 of the 196 (10%) patients, which could not be explained by tumour recurrence or progressive disease. All these patients were PPI users. An association between CgA levels and the use of PPI has already been described: a Dutch group published a cross-sectional study of 114 dyspeptic patients and showed that CgA levels were higher during long-term PPI treatment than during H2RA treatment, or no treatment ([@bib9]). [@bib5] observed in six of seven patients a significant decrease of CgA levels after discontinuation of omeprazole. These studies suggested that decrease in acidity leads to release of gastrin. Elevated gastrin leads to hyperplasia of ECL cells and, subsequently, to an increase in CgA levels ([@bib12]; [@bib9]). However, longitudinal studies investigating the effect of PPIs on CgA levels in patients with NET are lacking. In our group of NET patients, the elevated CgA levels significantly decreased, or even returned to normal, after discontinuation of gastric acid inhibition completely. A similar decrease was observed after replacement of PPI by H2RA.

A discontinuation of PPI of 2 weeks seemed a reasonable period in which to expect a decrease, similar to the report of Giusti *et al.* However, two patients (patients 6 and 7) with CgA levels \>10 times the upper limit of normal showed an 81--89% decrease, but did not reach the normal range. Possibly, in patients with such extreme high values, a longer discontinuation is needed. It has also been suggested that cytochrome P450 2C19 (CYP2C19) might have a role in the metabolising of PPI. Even a five-fold higher exposure to PPIs has been observed in poor metabolisers (PMs) than in extensive metabolisers of CYP2C19 ([@bib2]; [@bib5]). As the prevalence of PMs in Caucasian people is 1--3%, in some cases, the CgA could still be false positive after 2 weeks of discontinuation.

The two patients (patients 15 and 18) achieved a decrease \<40%. Their CgA levels returned back to the precious levels (data not shown). Apparently, the CgA results were explained by both NET disease and PPI use. Since both the biological and assay variation of CgA, NET disease and PPI use might affect the CgA concentration, it is of crucial importance to stop PPI, to exclude the PPI influence on CgA levels. Patient 18 with liver metastases suffered also from renal failure (glomerular filtration rate=36 ml per minute per 1.73 m^2^), but even then the CgA level decreased with 35% ([@bib7]).

Of the 122 patients, 24 (20%) with high CgA levels used PPI. Examination of the medical reports showed that the concentration of CgA levels was fully attributed to the disease. In the group of 55 patients with normal CgA levels, 5 (9%) were PPI users. The duration of PPI use of these patients was unknown, but [@bib9] suggested that the longer the use of PPI, the higher the CgA levels will be. In the future, all patients should discontinue PPI use in order to obtain a reliable CgA level, irrespective of tumour activity or duration of PPI use.

In our study population, there was no difference in CgA (percentage) decrease between patients who stopped acid inhibition completely and patients who replaced their PPI by H2RA. The use of H2RA did not affect the CgA levels, in contrast to PPI use. Proton pump inhibitor is a therapy that almost completely suppresses gastric acid. This is achieved by influencing the enzyme H^+^/K^+^-ATP-ase of the parietal cells (gastric proton pump). This acid suppression leads to an increase of gastrin, which is a trophic factor for hyperplasia of ECL cells. Apparently, the use of H2RA did not cause such hyperplasia of the ECL cells in this group of patients that it may lead to an increase of CgA. Although our H2RA group is relatively small, this finding confirms the results of [@bib4]) who reported increased parietal cell height, mass and number in omeprazole-treated patients compared with ranitidine-treated patients.

In conclusion, we recommend to cease or replace PPI by H2RA, to obtain a reliable value of CgA. A discontinuation of 2 weeks is usually sufficient.
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###### Characteristics of the total study population

                                      ***N*=196**
  ----------------------------------- -------------
  *Sex*                                
   Male                               88 (45%)
   Female                             108 (55%)
                                       
  *Age (years)*                        
   Median (range)                     64 (18--89)
                                       
  *Primary tumour site*                
   Appendix                           5 (3%)
   Small bowel                        86 (44%)
   Large bowel                        22 (11%)
   Lung                               21 (10%)
   Pancreas                           17 (9%)
   Other                              4 (2%)
   Unknown                            41 (21%)
                                       
  *Metastases*                         
   No                                 57 (29%)
   Yes                                139 (71%)
                                       
  *Carcinoid syndrome*                 
   No                                 66 (34%)
   Yes                                130 (66%)
                                       
  *GFR*                                
   Normal                             171 (87%)
   Decreased                          25 (13%)
                                       
  *Number of CgA measurements*         
   Median (range)                     6 (2--27)
                                       
  *CgA level*                          
   Normal                             55 (28%)
   Elevated (attributed to NET)       122 (62%)
   Elevated (not attributed to NET)   19 (10%)
                                       
  *PPI use*                            
   No                                 145 (74%)
   Yes                                51 (26%)

Abbreviations: CgA=chromogranin A; GFR=glomerular filtration rate; NET=neuroendocrine tumour; PPI=proton pump inhibitor.

###### Change in CgA levels in 19 patients after discontinuation of PPIs treatment

  **Patient**   **Sex, age (years)**    **Grade**  **Primary site**    **Status of disease**   **Carcinoid syndrome**  **GFR (ml per minute per 1.73 m^2^)**    **Replacement**  **CgA (*μ*g l^--1^) during PPI**   **CgA (*μ*g l^--1^) after PPI**   **CgA change (%)**
  ------------- ---------------------- ----------- ------------------ ----------------------- ------------------------ --------------------------------------- ----------------- ---------------------------------- --------------------------------- --------------------
  1             F, 63                      G1      Appendix                     NED                      NA            85                                            H2RA        425                                120                               −72
  2             F, 51                      G2      Lung                         NED                      NA            86                                            H2RA        307                                42                                −86
  3             F, 54                      G2      Lung                         NED                      NA            76                                            Stop        178                                51                                −71
  4             F, 42                      G1      Lung                         NED                      NA            72                                            Stop        123                                15                                −88
  5             M, 65                      G1      Small bowel                  NED                      NA            95                                            Stop        266                                40                                −85
  6             F, 77                      G1      Small bowel                  NED                      NA            93                                            Stop        1310                               245                               −81
  7             F, 61                      G1      Small bowel                  NED                      NA            50                                            Stop        1610                               181                               −89
  8             F, 65                      G1      Small bowel                  NED                      NA            77                                            H2RA        206                                48                                −77
  9             M, 76                      G1      Small bowel                  NED                      NA            90                                            H2RA        390                                65                                −83
  10            F, 67                      G1      Pancreas                     NED                      NA            102                                           Stop        404                                56                                −86
  11            M, 75                      G1      Small bowel                  NED                      NA            59                                            Stop        576                                101                               −82
  12            M, 68                      G1      Pancreas                     SD                      Yes            82                                            H2RA        1367                               332                               −76
  13            F, 67                      G1      Small bowel                  SD                      Yes            78                                            H2RA        588                                148                               −75
  14            F, 50                      G1      Pancreas                     SD                       No            78                                            Stop        1330                               305                               −77
  15            F, 66                      G1      Small bowel                  SD                       No            60                                            Stop        646                                436                               −33
  16            F, 56                      G1      Unknown                      SD                      Yes            72                                            H2RA        235                                38                                −84
  17            F, 60                      G1      Unknown                      SD                      Yes            67                                            Stop        872                                421                               −52
  18            M, 78                      G1      Small bowel                  SD                      Yes            36                                            Stop        589                                380                               −35
  19            M, 67                      G1      Small bowel                  SD                       No            124                                           Stop        587                                95                                −84

Abbreviations: CgA=chromogranin A; F=female; GFR=glomerular filtration rate; H2RA=H~2~-receptor antagonist; M=male; NA=not applicable; NED=no evidence of disease; PPI=proton pump inhibitor; SD=stable disease.
